Research Article
A Novel Clinical Scoring Model for Interventional Therapy in Chronic Total Occlusion of the Coronary Artery
Table 6
Comparison of data between different operator-CTO score groups.
| | | Simple
(≤2分) | Medium
(3分) | Difficult
(4分) | Extremely difficult
(≥5) | F/χ2 | |
| | CTO-PCI number | N = 103 | N = 24 | N = 13 | N = 4 | | | | Age (years) | 62.95 ± 10.95 | 61.54 ± 11.79 | 57.69 ± 14.27 | 63.25 ± 12.15 | 0.85 | 0.47 | | Male | 75 (72.8%) | 22 (91.7%) | 12 (92.3%) | 4 (100%) | 5.96 | 0.10 | | BMI (kg/m2) | 24.17 ± 3.22 | 24.31 ± 2.98 | 24.68 ± 3.72 | 25.15 ± 2.89 | 0.91 | 0.44 | | Hypertension | 71 (68.9%) | 16 (66.7%) | 8 (61.5%) | 3 (75.0%) | 0.15 | 0.93 | | Hyperlipidemia | 51 (49.5%) | 17 (70.8%) | 8 (61.5%) | 3 (75.0%) | 4.33 | 0.12 | | Impaired glucose tolerance | 36 (35.0%) | 8 (33.3%) | 4 (30.8%) | 2 (50.0%) | 0.03 | 0.99 | | Smoking | 45 (43.7%) | 11 (45.8%) | 10 (76.9%) | 1 (25.0%) | 2.59 | 0.27 | | Previous PCI history | 48 (46.6%) | 11 (45.8%) | 3 (23.1%) | 1 (25.0%) | 3.40 | 0.18 | | Previous CABG history | 0 | 0 | 1 (7.7%) | 0 | 4.33 | 0.12 | | Previous MI history | 33 (32.0%) | 8 (33.3%) | 3 (23.1%) | 0 | 0.50 | 0.78 | | ≥NYHA III | 34 (33.0%) | 8 (33.3%) | 5 (38.5%) | 1 (25.0%) | 0.03 | 0.98 | | ≥CKD III | 11 (10.7%) | 1 (4.2%) | 0 | 2 (50.0%) | 5.21 | 0.07 | | Acute coronary syndrome | 93 (90.3%) | 21 (87.5%) | 12 (92.3%) | 4 (100%) | 0.51 | 0.82 | | LVEF＜40% | 11 (10.7%) | 1 (4.2%) | 0 | 1 (25.0%) | 1.40 | 0.49 | | Angiographic features | | CTO target vessel | | | | | 16.56 | ＜0.05 | | LAD | 48 (46.6%) | 5 (20.8%) | 7 (53.8%) | 1 (25.0%) | | | | LCX | 8 (7.8%) | 6 (25.0%) | 0 | 0 | | | | RCA | 47 (45.6%) | 12 (50.0%) | 6 (46.2%) | 3 (75.0%) | | | | LM | 0 | 1 | 0 | 0 | | | | Collateral circulation, Rentrop, ＜2 | 25 (24.3%) | 10 (41.7%) | 7 (53.8%) | 4 (100%) | 12.23 | ＜0.01 | | Blunt occlusion | 48 (46.6%) | 18 (75.0%) | 13 (100%) | 4 (100%) | 26.95 | ＜0.01 | | Calcification | 28 (27.2%) | 12 (50.0%) | 7 (53.8%) | 1 (25.0%) | 6.19 | ＜0.05 | | Curvature | 93 (90.3%) | 23 (95.8%) | 11 (84.6%) | 4 (100%) | 1.05 | 0.59 | | Occlusion length ≥20 mm | 92 (89.3%) | 20 (83.3%) | 11 (84.6%) | 4 (100%) | 0.62 | 0.73 | | Distal occlusion | 50 (48.5%) | 14 (58.3%) | 10 (76.9%) | 4 (100%) | 6.92 | ＜0.05 | | Initial occlusion | 44 (42.7%) | 13 (54.2%) | 9 (69.2%) | 3 (75.0%) | 5.08 | 0.08 | | In-stent occlusion | 11 (10.7%) | 8 (33.3%) | 1 (7.7%) | 0 | 7.90 | ＜0.05 | | PCI features | | Forward single-guidewire technology | 76 (73.8%) | 13 (54.2%) | 4 (30.8%) | 1 (25.0%) | 13.76 | ＜0.01 | | Forward double-guidewire technology | 26 (25.2%) | 8 (33.3%) | 3 (23.1%) | 0 | 1.71 | 0.66 | | Intravascular ultrasound guidance/exploration | 29 (28.2%) | 3 (12.5%) | 4 (30.8%) | 0 | 2.87 | 0.24 | | Intervention strategy conversion | 30 (29.1%) | 10 (41.7%) | 7 (53.8%) | 1 (25.0%) | 4.19 | 0.23 | | 7F guide tube | 57 (55.3%) | 18 (75%) | 12 (92.3%) | 2 (50.0%) | 7.08 | ＜0.05 | | X-ray fluoroscopy time | 62.34 ± 16.03 | 83.32 ± 12.07 | 90.86 ± 10.25 | 86 | 2476.11 | ＜0.01 | | Dosage of the contrast agent | 166.88 ± 39.30 | 213.18 ± 25.71 | 251.43 ± 31.85 | 210 | 2782.87 | ＜0.01 | | CTO-PCI technical success | 99.0% | 87.5% | 53.8% | 25.0% | 173.10 | ＜0.01 | | CTO-PCI procedural success | 96.1% | 87.5% | 53.8% | 25.0% | 154.69 | ＜0.01 |
|
|
